Skip to main content

Table 2 Western blot analysis results for FMRP, mGluR5, GABRβ3 and NSE and their ratios in BA9a

From: Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study

Children Control Autistic Change P value Cohen's d
FMRP/NSE 0.08 ± 0.057 0.123 ± 0.069 ↑53% ns 0.66
mGluR5 dimer/NSE 0.158 ± 0.175 0.409 ± 0.101 ↑159% 0.013b 1.93b
mGluR5 total/NSE 0.167 ± 0.182 0.443 ± 0.123 ↑165% 0.014b 1.90b
mGluR5 dimer/mGluR5 total 0.867 ± 0.154 0.93 ± 0.042 ↑7.2% ns 0.66
GABRβ3/NSE 0.095 ± 0.052 0.161 ± 0.086 ↑69% ns 0.86b
NSE 17.4 ± 0.642 19.20 ± 2.67 ↑10.4% ns --
Adults Control Autistic Change P value Cohen's d
FMRP/NSE 0.24 ± 0.094 0.107 ± 0.068 ↓55% 0.017b 1.74b
mGluR5 dimer/NSE 0.186 ± 0.098 0.309 ± 0.188 ↑66% ns 0.74
mGluR5 total/NSE 0.191 ± 0.099 0.367 ± 0.187 ↑92% ns 1.05b
mGluR5 dimer/mGluR5 total 0.974 ± 0.023 0.982 ± 0.011 ↑0.8% ns 0.50
GABRβ3/NSE 0.177 ± 0.082 0.186 ± 0.103 ↑5.1% ns 0.09
NSE 17.5 ± 3.17 18.8 ± 2.3 ↑1.3% ns -
  1. aFMRP, fragile X mental retardation protein; mGluR5, metabotropic glutamate receptor 5; GABRβ3, γ-aminobutyric acid (GABA) A receptor β3; NSE, neuron-specific enolase; BA9, Brodmann's area 9; ns, not significant; bstatistically significant.